drugset / Trial / NCT04943159

Afamelanotide in Patients Suffering With Acne Vulgaris

NCT04943159 ↗

Phase 2 Completed 3 enrolled Clinuvel Pharmaceuticals Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the effect of afamelanotide on the facial inflammatory acne-related lesions in patients with mild to moderate acne vulgaris, including tolerability of afamelanotide by patients with moderate acne vulgaris and effects of the treatment on quality of life in eligible patients.

Timeline

Start
2010-08-24
Primary completion
2011-03-08
Completion
2011-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Afamelanotide Peptide — Subcutaneous

Indications